> Canada's Medicure plans to raise $25 million in a private placement to fund clinical development of its two lead products. Release
> DeCode genetics has reached an agreement with the FDA on the design of a Phase III trial of DG031 to prevent heart attacks. Report
> Chutes & Ladders: Epix Pharmaceuticals has announced that interim CEO Michael Astrue is resigning and will be replaced by Michael Kauffman, CEO of Predix. Epix has a deal to acquire Predix for $90 million in stock. Report
> Emisphere Technologies has warned it may not have enough cash to fund operations through July. Report
> Ipca Laboratories has opened a new manufacturing facility in India. Report
> Hollis-Eden Pharmaceuticals has filed an INDA to start a Phase I trial of Neumune. Article
> CROs are saying that the new focus on Phase IV trials should be good for business. Article
> Mesa Labs has acquired Raven Biological Laboratories for $6.75 million in cash and stock. Release
And Finally… Warm weather-related diseases like malaria, dengue fever and West Nile virus are rapidly expanding their range as global warming heats the planet. Report